We are a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.
Yamin 'Mo' Khan
CEO at hVIVO
"I am pleased to update the market that we expect to report positive (adjusted) EBITDA ahead of guidance for FY25. This was driven by stronger than expected operational delivery in Q4 2025, and the contractual protections embedded within our model.
"Following the acquisition of CRS and Cryostore we now offer a full end‑to‑end service platform from preclinical through to Phase III across multiple therapeutic areas. The integration of CRS and Cryostore is complete, and we are realising synergies across our four specialist service lines. Our purpose-built full-service early phase capabilities clearly differentiate us within the market and together with our strong and diverse pipeline, we reiterate our guidance for high single digit revenue growth in 2026."
Expected FY25 Revenue
Expected Adjusted EBITDA Margin
Cash 31 December 2025
FY26 Revenue Guidance
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
